<?xml version="1.0"?>
<rss version="2.0" xmlns:prism="http://purl.org/rss/1.0/modules/prism/">
  <channel>
    <title>JAMA Psychiatry: Pathology &amp; Laboratory Medicine Topic Collection</title>
    <link>http://archpsyc.jamanetwork.com/</link>
    <description>
    </description>
    <language>en-us</language>
    <pubDate>Wed, 26 Dec 2012 00:00:00 GMT</pubDate>
    <lastBuildDate>Tue, 01 Jan 2013 00:50:29 GMT</lastBuildDate>
    <generator>Silverchair</generator>
    <managingEditor>editor@archpsyc.jamanetwork.com</managingEditor>
    <webMaster>webmaster@archpsyc.jamanetwork.com</webMaster>
    <item>
      <title>Association of Plasma Clusterin Concentration With Severity, Pathology, and Progression in Alzheimer Disease Plasma Clusterin and Alzheimer Disease </title>
      <link>http://archpsyc.jamanetwork.com/article.aspx?articleID=210840</link>
      <pubDate>Thu, 01 Jul 2010 00:00:00 GMT</pubDate>
      <author>Thambisetty M, Simmons A, Velayudhan L, et al. </author>
      <description>&lt;span class="paragraphSection"&gt;&lt;div class="boxTitle"&gt;Context&lt;/div&gt;Blood-based analytes may be indicators of pathological processes in Alzheimer disease (AD).&lt;div class="boxTitle"&gt;Objective&lt;/div&gt;To identify plasma proteins associated with AD pathology using a combined proteomic and neuroimaging approach.&lt;div class="boxTitle"&gt;Design&lt;/div&gt;Discovery-phase proteomics to identify plasma proteins associated with correlates of AD pathology. Confirmation and validation using immunodetection in a replication set and an animal model.&lt;div class="boxTitle"&gt;Setting&lt;/div&gt;A multicenter European study (AddNeuroMed) and the Baltimore Longitudinal Study of Aging.&lt;div class="boxTitle"&gt;Participants&lt;/div&gt;Patients with AD, subjects with mild cognitive impairment, and healthy controls with standardized clinical assessments and structural neuroimaging.&lt;div class="boxTitle"&gt;Main Outcome Measures&lt;/div&gt;Association of plasma proteins with brain atrophy, disease severity, and rate of clinical progression. Extension studies in humans and transgenic mice tested the association between plasma proteins and brain amyloid.&lt;div class="boxTitle"&gt;Results&lt;/div&gt;Clusterin/apolipoprotein J was associated with atrophy of the entorhinal cortex, baseline disease severity, and rapid clinical progression in AD. Increased plasma concentration of clusterin was predictive of greater fibrillar amyloid-β burden in the medial temporal lobe. Subjects with AD had increased clusterin messenger RNA in blood, but there was no effect of single-nucleotide polymorphisms in the gene encoding clusterin with gene or protein expression. &lt;span style="font-style:italic;"&gt;APP&lt;/span&gt;/&lt;span style="font-style:italic;"&gt;PS1&lt;/span&gt; transgenic mice showed increased plasma clusterin, age-dependent increase in brain clusterin, as well as amyloid and clusterin colocalization in plaques.&lt;div class="boxTitle"&gt;Conclusions&lt;/div&gt;These results demonstrate an important role of clusterin in the pathogenesis of AD and suggest that alterations in amyloid chaperone proteins may be a biologically relevant peripheral signature of AD.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">67</prism:volume>
      <prism:number xmlns:prism="prism">7</prism:number>
      <prism:startingPage xmlns:prism="prism">739</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">748</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/archgenpsychiatry.2010.78</prism:doi>
      <guid>http://archpsyc.jamanetwork.com/article.aspx?articleID=210840</guid>
    </item>
  </channel>
</rss>